The VDZ-CDST (Vedolizumab-Clinical Decision Support Tool) in the CD Calculator employs and digitizes a validated scoring system¹ for Healthcare Professionals (HCPs) to identify Crohn’s Disease* (CD) patients likely to respond positively to 26 weeks of vedolizumab (VDZ) therapy. Patients identified by the CDST as high-probability responders (>19 points) are more likely to achieve better outcomes after 26 weeks compared to intermediate- (>13 and ≤19 points) and low-probability (≤13 points) responders.

Complete the 5 questions below, ensuring you enter values for Baseline Albumin and Baseline C-reactive protein with the correct units. Press the calculate button to receive a probability score of low, medium, or high, indicating the likelihood of a patient's positive response to 26 weeks of therapy.

Please enter your inputs in the following fields:

*All fields are required

Prior bowel surgery?
Prior TNF-antagonist therapy?
Prior fistulising disease?
Baseline Albumin:
Baseline C-reactive protein:
Results:
information-icon information-icon information-icon
The score for your patient is:
Leading to:

¹Dulai PS, Boland BS, Sing S, et al Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease. Gastroenterology. 2018;155:687-695.

The results of the tool may provide helpful assistance on option, but for any treatment methodology and decisions, the prescribing HCP should consider additional patient information and other clinical data. The validity of the tool response will be subject to the questions being correctly understood and addressed by the user.

This is part of a Takeda promotional initiative for Entyvio.

* Entyvio is indicated for adult patients with moderately to severely active ulcerative colitis or Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF(α) antagonist. For adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and had an inadequate response with or lost response to antibiotic therapy.

takeda-logo

Takeda Pharmaceuticals (Hong Kong) Limited
Morrison Hill Post Office,
P O Box 47256, Hong Kong
Tel: +852-2133 9800